JCR Pharmaceuticals Receives Marketing Authorization in Kuwait for IZCARGO™, a Blood-Brain Barrier-Penetrating Enzyme Replacement Therapy for Hunter Syndrome

Posted on by sHq_LoGiNz

HYOGO, Japan–(BUSINESS WIRE)–JCR announced that IZCARGO, an enzyme replacement therapy indicated for Hunter syndrome, received marketing authorization in Kuwait.

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.